Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Specialties
Hematology
Oncology
Musculoskeletal Disorder
Rare Disease
Metabolic Disorder
Cardiovascular Disease
Ophthalmology
Neurology
Infectious Disease
View all Specialties
Technologies
Cell Therapy
MSC
iPSC
Gene Therapy
Genome Editing
Extracellular Vesicles
CAR-T Therapy
TCR Therapy
Tissue-Engineering & Biomaterials
View all Technologies
Topics
Treatment
Immuno-Oncology
Trial Updates
Perspectives
Manufacturing
COVID-19
View all Topics
Conferences
ASH 2022
TCT 2022
Meeting on the Med 2022
ICLE 2022
Advanced Therapies Week 2022
TERMIS 2021
ESGCT 2021
Meeting on the Mesa 2021
Advanced Therapies 2021
View all Conferences
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
NKG2D
1:51
Allogeneic NKX101 in liver cancer
Kanya Rajangam
• 13 Oct 2021
1:40
Innovations within the CAR T-cell field
Hong Ma
• 19 Feb 2021
2:56
Allogenic NKX101 in r/r AML
James Trager
• 22 Feb 2021
2:21
A non-gene edited approach to allogeneic CAR-T development
Filippo Petti
• 6 Apr 2021
3:24
CYAD-101 & alloSHRINK: allogeneic CAR-T cell therapy in MSS mCRC
David Gilham
• 22 Feb 2021
2:29
CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS
David Gilham
• 22 Feb 2021
